A carregar...

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer

BACKGROUND: Approximately 15%–23% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), which leads to the activation of signaling pathways that stimulate cell proliferation and survival. HER2-targeted therapy has substantially improved outcomes in patients with HER2-positiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mohd Sharial, M. S. N., Crown, J., Hennessy, B. T.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3501233/
https://ncbi.nlm.nih.gov/pubmed/22865781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds200
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!